Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Acrivon Therapeutics, Inc. (ACRV) had Stock-Based Compensation of $14.72M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-77.91M |
|
-- |
|
-- |
|
$84.11M |
|
$-84.11M |
|
$6.21M |
|
$-77.91M |
|
$-77.91M |
|
$-77.91M |
|
$-77.91M |
|
$-77.91M |
|
$-77.91M |
|
$-84.11M |
|
$-83.19M |
|
38.51M |
|
38.51M |
|
$-2.02 |
|
$-2.02 |
|
| Balance Sheet Financials | |
$120.44M |
|
$4.89M |
|
$9.27M |
|
$129.72M |
|
$15.66M |
|
-- |
|
$1.54M |
|
$17.20M |
|
$112.52M |
|
$112.52M |
|
$112.52M |
|
31.65M |
|
| Cash Flow Statement Financials | |
$-63.66M |
|
$66.10M |
|
$-0.75M |
|
$40.02M |
|
$41.70M |
|
$1.69M |
|
|
Stock-Based Compensation |
$14.72M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.69 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-65.33M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-69.24% |
|
-69.24% |
|
-60.06% |
|
-69.24% |
|
$3.56 |
|
$-1.70 |
|
$-1.65 |
|